{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T18:19:26Z","timestamp":1774289966429,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clinthera.2020.06.002","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T01:28:01Z","timestamp":1597109281000},"page":"1483-1493.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Approach to Evaluating QT Prolongation of Quetiapine Fumarate in Late Stage of Clinical Development Using Concentration-QTc Modeling and Simulation in Japanese Patients With Bipolar Disorder"],"prefix":"10.1016","volume":"42","author":[{"given":"Risa","family":"Fukushi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Katashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanji","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitsugu","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.06.002_bib1","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1378\/chest.98.2.482","article-title":"Haloperidol-induced torsades de pointes","volume":"98","author":"Kriwisky","year":"1990","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2020.06.002_bib3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02244923","article-title":"Seroquel: biochemical profile of a potential atypical antipsychotic","volume":"112","author":"Saller","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2020.06.002_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s002130050492","article-title":"Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia","volume":"135","author":"Gefvert","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2020.06.002_bib6","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s00213-018-4977-6","article-title":"Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression","volume":"235","author":"Murasaki","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2020.06.002_bib7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1185\/03007995.2013.794774","article-title":"Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications","volume":"29","author":"Bui","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2020.06.002_bib8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40262-013-0127-9","article-title":"Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia","volume":"53","author":"Li","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2020.06.002_bib9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","article-title":"Clinical pharmacokinetics of quetiapine: an atypical antipsychotic","volume":"40","author":"DeVane","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2020.06.002_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/cap.2007.0084","article-title":"Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders","volume":"18","author":"Winter","year":"2008","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.clinthera.2020.06.002_bib11","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/0091270009344855","article-title":"Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation","volume":"49","author":"Chapel","year":"2009","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.06.002_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JCP.0b013e31827c0314","article-title":"A\u00a0thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and\/or CYP3A4 and a comparison to quetiapine and ziprasidone","volume":"33","author":"Potkin","year":"2013","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2020.06.002_bib13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12888-019-2181-9","article-title":"Long-term mood\/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression","volume":"19","author":"Kanba","year":"2019","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.clinthera.2020.06.002_bib14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1542-474X.2003.08413.x","article-title":"The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920","volume":"8","author":"Fridericia","year":"2003","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.clinthera.2020.06.002_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10928-012-9292-y","article-title":"The effects of active metabolites on parameter estimation in linear mixed effect models of concentration-QT analyses","volume":"40","author":"Bonate","year":"2013","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.clinthera.2020.06.002_bib16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","article-title":"Scientific white paper on concentration-QTc modeling","volume":"45","author":"Garnett","year":"2018","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.clinthera.2020.06.002_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neulet.2017.11.029","article-title":"Effects of norquetiapine, the active metabolite of quetiapine, on cloned hERG potassium channels","volume":"664","author":"Lee","year":"2018","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.clinthera.2020.06.002_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0014-2999(02)02074-5","article-title":"A\u00a0comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs","volume":"450","author":"Kongsamut","year":"2002","journal-title":"Eur J Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820302848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820302848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:41Z","timestamp":1758963161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820302848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0149291820302848"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.06.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approach to Evaluating QT Prolongation of Quetiapine Fumarate in Late Stage of Clinical Development Using Concentration-QTc Modeling and Simulation in Japanese Patients With Bipolar Disorder","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}